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Health-related Quality of Life, Fatigue, and Depression
Under Low-Dose IFN-a Therapy in Melanoma Patients
Katrin Reuter,*w Karoline Albrecht,w Harald Seelig,zy Frank Meiss,w
Cornelia Mauch,8 Nicole Kreuzberg,8 and Dorothe´e Nashanz
Summary: Adjuvant melanoma treatment with interferon-a (IFN-
a) has proven to be accompanied by several side eﬀects and to
decrease patients’ health-related quality of life (HRQOL), fatigue
and depression being essential factors at that. Although a large
body of evidence exists for HRQOL under IFN-a therapy, we now
speciﬁcally address this topic combining the HRQOL survey in the
ﬁrst months of IFN-a low-dose treatment with a structured
assessment of relevant neuropsychiatric side eﬀects, fatigue and
depression, with speciﬁc validated assessment tools. The present
study is a longitudinal observational study assessing fatigue,
depression, and HRQOL with speciﬁc assessment tools at 3
assessment points over 6 months. The IFN-a treatment group
consisted of 48 patients with current IFN-a therapy (3MU 3 times
weekly) from a consecutively recruited melanoma collective and
compared with a parallelized nontreatment group (n=48) in
routine clinical practice. A descriptive analysis and generalized
linear models were applied to compare the groups. Physical fatigue
increased signiﬁcantly within the ﬁrst months of IFN-a treatment,
whereas cognitive and emotional fatigue and depression symptoms
did not show this increase. The hypothesis of a signiﬁcant deteri-
oration of HRQOL after IFN-a initiation was not conﬁrmed. The
treatment group did, however, show a diﬀerent course of global
HRQOL than the comparison group, with a signiﬁcant improve-
ment in the nontreatment group. Patients under low-dose IFN-a
therapy primarily suﬀer from physical side eﬀects, mainly physical
fatigue, in the early phases of treatment. The HRQOL improve-
ment evident in the nontreatment group was not observed in the
IFN-a group.
Key Words: melanoma, interferon-a, health-related quality of life,
depression, fatigue
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The therapeutic management of malignant melanoma hasundergone promising changes over the past years.1
However, interferon-a (IFN-a) remains the only approved
agent in adjuvant melanoma treatment, despite the recent
signiﬁcant developments of targeted therapies in metastatic
melanoma.2–4 Although no international consensus exists
on optimal interferon dosage and schedules, the recent
German S-3 guidelines recommend 18 months of low-dose
IFN-a for high-risk melanomas (stages II–III according to
the American Joint Committee on Cancer (AJCC) classi-
ﬁcation of 20095), with an optional oﬀer of high-dose IFN-
a for stage III patients.2 Identiﬁcation of the optimal IFN-a
treatment regimen is still pending, as existing meta-analyses
have failed to identify the optimal dose and duration of
treatment.4,6 Treatment recommendations therefore have to
be based on the beneﬁt versus side eﬀects deliberation of the
diﬀerent regimens.4,7 IFN-a treatment is accompanied by
several side eﬀects and a deterioration of patients’ quality
of life.8–12 Side eﬀects range from physical ﬂu-like symp-
toms, which mainly appear in the ﬁrst weeks of treatment,
to longer lasting hepatic and hematopoietic symptoms and
psychiatric side eﬀects, including fatigue, depression, and
anxiety.8–11,13,14 Fatigue and depression are 2 of the most
common neuropsychiatric side eﬀects of IFN-a therapy and
they are a frequent cause for dose reduction or interruption
of treatment.13,15,16 Although fatigue has been found with
an incidence of 80%–90%, IFN-a-induced depression rates
vary largely between studies depending on the assessment
tools and the IFN-a treatment regimen employed.13,15,17,18
Studies indicate that IFN-a toxicities are most pronounced
in the ﬁrst 4–12 weeks, particularly in the high-dose regi-
men.9,19 Large randomized controlled IFN-a trials have
previously added the assessment of health-related quality of
life (HRQOL) to the evaluation of eﬀectiveness9,12 but, to
our knowledge, only 1 study has investigated the longi-
tudinal course of depression, fatigue, and HRQOL simul-
taneously. The study showed a signiﬁcant increase from
baseline to the 6-month assessment in somatic complaints,
depression, and fatigue with a concurrent reduction in
HRQOL in 16 patients treated with high-dose IFN-a.10 As
low-dose therapy is the predominant IFN-a treatment
regimen in Germany,2 detailed knowledge on these side
eﬀects in the course of low-dose treatment is crucial for
adequate interventions assuring patients’ quality of life and
treatment adherence. Within large multicentre trials con-
ducted by the Dermatologic Cooperative Oncology Group
(DECOG-Trials) the examination of treatment with low-
dose IFN-a, has shown inconsistent ﬁndings regarding the
course of global HRQOL and functioning.9,20 Therefore,
there is a need to address both HRQOL and predominant
toxicities under low-dose IFN-a, to determine the preva-
lence and distinguish the courses of relevant side eﬀects and
HRQOL.
The aim of this study is to concurrently investigate the
initial eﬀect of low-dose IFN-a on HRQOL, fatigue and
depression, assessed with speciﬁc, standardized assessment
tools, in comparison with a nontreatment comparison
group under standard clinical settings. We hypothesized to
ﬁnd an increase in fatigue and depression symptoms in the
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ﬁrst months of IFN-a treatment associated with a decrease
of global HRQOL in comparison with no signiﬁcant
changes in the nontreatment group.
PATIENTS AND METHODS
Sample
The study was part of a broader research project on
psychosocial aspects and interventions in melanoma patients
and received ethical approval from the Ethics Committees
for Medical Research in Freiburg and Cologne, Germany
(ClinicalTrials.gov NCT00963261). Between July 2009 and
December 2011, a consecutive sample of melanoma patients
was recruited in the Skin Cancer Centers of Freiburg and
Cologne after giving written informed consent. Patients were
asked to participate in this observational questionnaire study if
they had histologically proven diagnosis of melanoma, AJCC
clinical stages Ib–IIIc.5 Exclusion criteria were other tumors
(except for epithelial nonmetastatic skin cancer) within the past
10 years, permanent infectious diseases, age less than 18 years,
or insuﬃcient command of the German language. From July
2009 until December 2011, a total of 466 patients was recruited
(Freiburg: N=288, Cologne: N=178).
For the present study, a subgroup analysis with patients
currently under low-dose IFN-a therapy and a comparable
patient group without treatment was conducted. Patients were
selected for the analysis based on the following inclusion cri-
teria: (a) tumor stages indicating IFN-a therapy eligibility
according to guideline recommendations of 2008 (AJCC clin-
ical stages Ib–IIIc, with Z1.5mm tumor thickness21); (b)
completed primary surgery no longer than 2 months before
recruitment; and (c) no other adjuvant systemic melanoma
treatments. Treatment decisions for the sample were entirely
based on the routine clinical practice in the 2 clinics, inde-
pendent of the study. Patients who started low-dose IFN-a
therapy (3MU 3 times weekly) within 3 months of completing
the baseline questionnaire made up the IFN-a treatment group
(n=48). Subsequently, a comparison group parallelized for
basic sociodemographic and medical variables without IFN-a
therapy was drawn from the remaining sample who also ful-
ﬁlled the deﬁned inclusion criteria but had declined IFN-a
treatment (n=48). Table 1 summarizes the sample charac-
teristics of the 2 groups, displaying no signiﬁcant diﬀerences
between the groups.
Procedure
Eligibility of patients was screened before initial contact,
and eligible patients were informed of the study and its pur-
pose. Baseline questionnaires (t0) were distributed in the Skin
Cancer Centers and completed within 2 months of primary
surgery, with the subsequent questionnaires mailed to the
patients in self-addressed stamped envelopes and completed at
3 and 6 months (t1 and t2) after baseline. The treatment for the
IFN-a therapy group was started between t0 and t1.
Measures
Fatigue
Fatigue was assessed with the European Organization
for Research and Treatment of Cancer (EORTC) fatigue
module, the EORTC QLQ-FA13.22 This 13-item self-rating
scale is the fatigue module of the Quality of Life assessment
battery, supplementing the core quality of life questionnaire
also used in this study. It consists of 3 subscales (physical,
emotional, and cognitive fatigue) and 2 single items indi-
cating “interference with daily life” and “social sequelae” of
fatigue. According to the EORTC scoring recom-
mendations, the raw scores are standardized with a linear
transformation, so that the standardized scale scores range
from 0 to 100.23
Depression
Symptoms of depression were assessed with the
depression scale of the German version of the Hospital
Anxiety and Depression Scale (HADS-D24). This scale is
particularly appropriate for use with somatically ill patients
and has been repeatedly used in melanoma samples to
evaluate the level of depression symptoms.17,25 The out-
come score of the depression scale ranges from 0 to 21, with
2 cut-oﬀ scores deﬁned by the scoring manual of Z8 for
marginal depression and Z11 for moderate depression
cases.26
HRQOL
The EORTC Quality of Life Questionnaire (EORTC
QLQ-C3027) was applied as it is a well-validated and
commonly used HRQOL assessment tool in IFN-a trials. It
consists of 30 items and incorporates 1 global HRQOL
score, 5 functioning scales (physical, role, emotional, cog-
nitive, and social), and 8 symptom scales (fatigue, nausea/
vomiting and pain, dyspnea, sleep disturbance, appetite
loss, constipation, and diarrhea). The global score was
selected as the primary HRQOL outcome of this study,
with the functioning- and symptom scales comprising sec-
ondary HRQOL outcomes.
Statistics
Data were analyzed using SPSS 20 (IBM SPSS Statistics
20; IBM Corporation, Somers, New York). First, the com-
parability of the 2 groups at baseline was tested using t tests,
with independent samples. According to the observational
TABLE 1. Sample Characteristics by Comparison Group
Total Sample (n=96)
IFN-a
Group
(n=48)
Comparison
Group
(n=48)
Comparison
of the Groups
Age (y) [mean±SD] 52.0±14.6 54.2±12.5 t= 0.81
P=0.42
Sex (male:female) 30:18 25:23 w2=1.1
P=0.41
Marriage status
Married 31 31
Single 12 9 w2=1.3
P=0.73
Divorced 2 4
Widowed 2 3
Time since diagnosis
(mo) [mean±SD]
1.1±1.2 1.3±0.8 t= 0.97
P=0.33
Time since primary
surgery (mo)
[mean±SD]
0.1±0.6 0.2±0.4 t= 1.21
P=0.23
AJCC clinical stage [n (%)]
Ib 9 (19) 14 (29) w2=4.7
P=0.10
II 22 (46) 26 (54)
III 17 (35) 8 (17)
*Pr0.05.
AJCC indicates American Joint Committee on Cancer; IFN-a, inter-
feron-a.
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study design a descriptive analysis of the course of fatigue,
depression, and HRQOL of the 2 groups was conducted, by
an examination of the mean diﬀerences of each group over
time. For this purpose the diﬀerences in means of t0 versus t1
and t0 versus t2 were calculated for the treatment and the
observation group, respectively. These diﬀerences were
checked for clinical signiﬁcance according to the minimally
important diﬀerence approach, regarding diﬀerences of Z10
points on the EORTC scales as clinically signiﬁcant.28 To test
the signiﬁcance of diﬀerences in fatigue, depression, and global
HRQOL across time and compared with the control group
General Linear Models (GLM) for repeated measures were
conducted. An a-level of 0.05 was used for all statistical tests.
The few missing values at baseline (<5%) were substituted
with the group mean values and missing values at t1 and t2
were substituted with the last observation carried forward
method. A sensitivity analysis without the substitution of
missing values was conducted to check for discrepancies.
Because the results were comparable we refrained from pre-
senting both analyses.
RESULTS
Comparisons of Baseline Scores Between Groups
The baseline scores on the primary outcome measures
of fatigue, depression, and global HRQOL do not diﬀer
signiﬁcantly between the groups (P=0.144–0.597). Thus,
the groups were comparable at baseline. Signiﬁcant diﬀer-
ences on the t tests were only found for 2 of the secondary
outcome scores: EORTC QLQ-C30 social functioning
(t(94)= 2.06, P=0.04) and EORTC FA13 social
sequelae (t(94)=2.22, P=0.03). These diﬀerences suggest
lower baseline social functioning and more social hin-
drances in the IFN-a group and were therefore entered as
covariates in the GLM comparing the 2 groups. They did
not reveal divergent results (data not shown).
Course of Fatigue, Depression, and HRQOL
Table 2 shows the complete set of mean scores of the
scales of the EORTC fatigue module, the HADS depression
scale, and the EORTC QLQ-C30 over the 3 assessment
points for both the groups. Diﬀerences between baseline
and the latter scores (t1t0 and t2 t0) are presented in the
last 2 columns.
Fatigue
The descriptive analysis of diﬀerences in the means of
the fatigue module showed signiﬁcant increases in physical
fatigue (Fig. 1) and interference with daily under IFN-a.
The mean scores of the comparison group did not change
considerably on any of the fatigue subscales. The GLM
results of the EORTC QLQ-FA13 stress the diﬀerential
course of physical fatigue of the 2 groups with a highly
signiﬁcant interaction eﬀect (F2,188=9.12, P=0.000). The
interaction of time by group was, however, not signiﬁcant
for emotional and cognitive fatigue (Table 3). Although the
GLM model for emotional fatigue showed no signiﬁcant
eﬀects, the cognitive fatigue model revealed a signiﬁcant
group eﬀect (F1,94=8.19, P=0.005), indicative of sig-
niﬁcantly higher cognitive fatigue in the IFN-a group.
Depression
The HADS-D results revealed neither a clinically nor
statistical signiﬁcant change over time in both the groups
(Table 2). Thus, no signiﬁcant increase of depression
symptoms under IFN-a was evident in the sample (Fig. 1).
The GLM model did reveal a statistically signiﬁcant group
eﬀect (F1,94=6.75, P=0.011), with, however, subthres-
hold mean HADS-D depression scores in both groups at
each assessment point (Table 3). To further analyze this
signiﬁcant group eﬀect, we conducted w2 tests to compare
the number of patients with elevated depression scores in
the 2 groups. This explorative analysis revealed that in both
groups no more than 3 patients scored above the cut-oﬀ of
Z11 without signiﬁcant diﬀerences between the 2 groups at
any assessment point (t0: w2=0.32, P=1.00; t1: w2=1.1,
P=0.36; t2: w2=0.23, P=0.68).
HRQOL
The main HRQOL outcome (global HRQOL) did not
show a clinically signiﬁcant diﬀerence in means over time in
the treatment group (Table 2). The GLM model did,
however, reveal signiﬁcant time, group, and interaction
eﬀects of global HRQOL (see Table 3 for statistical prop-
erties). These signiﬁcant GLM results are based on a sig-
niﬁcant improvement of global HRQOL between baseline
and the 3 and 6 months’ assessment points in the compar-
ison group (+9.9 and +10.8) (Fig. 1). Diﬀerences in
means between the groups at t1 (13.6 points) and t2 (11.7
points) indicate clinically signiﬁcant lower global HRQOL
in the treatment group.
Concerning the secondary HRQOL outcomes the
descriptive analysis of the EORTC QLQ-C30 functioning
scales revealed no signiﬁcant changes in the functioning of
the treatment group (Table 2). Role and emotional func-
tioning did, however, improve substantially in the obser-
vation group over time. Clinically signiﬁcant increases in
the IFN-a group were found on the fatigue, dyspnea, and
appetite loss symptom scales.
DISCUSSION
This longitudinal observation study provides a diﬀer-
entiated analysis of HRQOL and relevant side eﬀects after
onset of low-dose IFN-a treatment from the patient’s per-
spective in routine clinical practice. We compared the
course of fatigue, depression, and global HRQOL of
patients at the initiation of IFN-a treatment and the ﬁrst
months of application, with that of a comparable obser-
vation group without treatment. Treatment decisions were
made in routine clinical practice, independent of the study.
Our hypothesis of a signiﬁcant decrease in global HRQOL
at IFN-a onset, as reported in 2 previous low-dose IFN-a
trials9,11 was not conﬁrmed by our data. Loquai et al29
report similar results for a group of 30 patients under PEG-
IFN, with an only marginal HRQOL deterioration, despite
several impairments and adverse eﬀects reported by the
patients. Garbe et al20 even found a better global HRQOL
and functioning in the low-dose IFN-a group compared
with the observation group. A possible explanation for this
phenomenon could be that patients receiving IFN-a cope
with the treatment side eﬀects in an eﬀective way, resulting
in a good HRQOL despite experiencing considerable side
eﬀects. Some patients appraise side eﬀects as a sign of
eﬀective treatment, which they are willing to tolerate for the
beneﬁt of doing what they can to ﬁght the cancer.30
However, based on the comparison of the treatment
group with the nontreatment group, the present study does
implicate a signiﬁcant eﬀect of IFN-a treatment on
HRQOL. Our ﬁndings suggest that patients without
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TABLE 2. Complete Presentation of Mean EORTC QLQ-FA13, HADS-D, and EORTC QLQ-C30 Scores at t0, t1, and t2 for the IFN-a Group
(n =48) and the Comparison Group (n =48)
Baseline t0 3mo t1 6mo t2
Diﬀerence t0
Versus t1*
Diﬀerence t0
Versus t2*
EORTC QLQ-FA13w
Physical fatigue
IFN-a group 30.6±28.6 47.7±29.7 43.2±29.9 17.1z 12.6z
Comparison group 23.3±25.1 23.3±28.1 19.1±20.8 0 4.2
Emotional fatigue
IFN-a group 20.6±21.9 23.3±23.6 24.2±23.5 2.7 3.6
Comparison group 16.8±21.4 16.0±24.9 15.4±23.6 0.8 1.4
Cognitive fatigue
IFN-a group 13.2±18.4 16.7±20.0 17.6±17.3 3.5 4.4
Comparison group 8.7±13.5 7.4±15.3 6.7±12.5 1.3 2.0
Interference with daily life
IFN-a group 23.6±32.2 43.7±34.5 38.9±30.2 20.1z 15.3z
Comparison group 16.3±27.4 16.0±28.3 11.1±19.8 0.3 5.2
Social sequelae
IFN-a group 14.5±27.2 12.5±23.4 17.4±28.3 2.0 2.9
Comparison group 4.3±16.3 6.2±22.4 3.5±12.4 1.9 00.8
HADS-Dy
Depression symptoms
IFN-a group 3.7±3.5 4.0±3.7 4.3±3.5 0.3 0.6
Comparison group 2.9±3.3 2.2±2.7 2.2±2.9 0.7 0.7
EORTC QLQ-C308
Global HRQOL
IFN-a group 64.5±22.7 64.1±22.2 66.9±22.0 0.4 2.4
Comparison group 67.8±24.3 77.7±23.2 78.6±21.1 9.9 10.8z
Physical functioning
IFN-a group 83.5±24.1 79.3±23.1 81.0±19.1 4.2 2.5
Comparison group 85.1±15.3 90.3±16.1 91.5±12.5 5.2 6.4
Role functioning
IFN-a group 61.7±37.5 59.0±32.2 63.2±30.7 2.7 1.5
Comparison group 66.0±31.9 81.9±30.1 86.1±23.9 15.9z 20.1z
Emotional functioning
IFN-a group 62.1±27.4 63.1±23.7 63.5±24.0 1.1 1.4
Comparison group 66.1±25.5 77.1±26.2 75.5±24.1 11.0z 9.4
Cognitive functioning
IFN-a group 76.0±25.5 74.3±27.3 73.6±24.0 1.7 2.4
Comparison group 84.0±20.6 87.1±23.9 87.8±19.4 3.1 3.8
Social functioning
IFN-a group 69.4±29.2 71.9±24.6 72.2±28.6 2.5 2.8
Comparison group 80.9±25.0 87.1±22.3 89.2±19.9 6.2 8.3
Fatigue
IFN-a group 27.4±26.9 44.7±26.2 40.2±24.4 17.3z 12.8z
Comparison group 22.7±24.9 22.9±28.1 18.1±21.1 0.2 4.6
Nausea/vomiting
IFN-a group 4.5±13.2 8.7±16.1 7.3±16.8 4.2 2.8
Comparison group 2.8±7.2 2.8±11.0 2.4±10.9 0 0.4
Pain
IFN-a group 23.6±30.9 22.6±30.3 26.0±30.9 1.0 2.4
Comparison group 18.8±25.9 12.8±24.6 13.2±24.1 6.0 5.6
Dyspnea
IFN-a group 11.1±21.0 25.0±31.9 21.5±27.9 13.9z 10.4z
Comparison group 15.3±26.6 18.8±26.5 13.9±22.6 3.5 1.4
Sleep disturbance
IFN-a group 29.9±39.0 32.6±35.4 38.2±31.5 2.7 8.3
Comparison group 24.3±29.8 17.4±25.7 14.6±23.7 6.9 9.7
Appetite loss
IFN-a group 13.2±24.5 23.6±32.9 18.1±29.1 10.4z 4.9
Comparison group 6.3±19.0 7.6±20.9 4.9±15.4 1.3 1.4
Constipation
IFN-a group 2.1±10.7 5.6±17.3 7.6±20.9 3.5 5.5
Comparison group 2.8±11.6 2.8±11.6 2.8±11.6 0 0
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adjuvant treatment recover better from diagnosis and pri-
mary treatment of melanoma, showing a higher HRQOL
up to half a year later than patients who undergo IFN-a
treatment. Thus, the negative eﬀect of IFN-a on HRQOL is
uncovered by the necessary comparison with a nontreat-
ment group. Although social functioning as one aspect
of HRQOL had lower baseline values in the IFN-a group,
the diﬀerence did not aﬀect the outcome on general
HRQOL.
The application of speciﬁc, validated assessment tools
for fatigue and depression in the present study revealed that
patients under low-dose IFN-a primarily suﬀer from
physical fatigue, rather than emotional and cognitive fati-
gue. Physical fatigue increased most substantially within the
ﬁrst 3 months of treatment and stayed elevated through the
6 months assessment point. This multidimensional, detailed
investigation adds new insight on the understanding of
IFN-a-induced fatigue: patients rather report feelings
TABLE 2. (continued)
Baseline t0 3mo t1 6mo t2
Diﬀerence t0
Versus t1*
Diﬀerence t0
Versus t2*
Diarrhea
IFN-a group 5.7±14.3 12.5±25.4 14.6±24.7 6.8 8.9
Comparison group 4.9±16.8 6.9±18.1 5.6±17.3 2.0 0.7
*Diﬀerence calculated as t1 t0 and t2 t0, respectively.
wStandardized EORTC QLQ-FA13 mean scores, ranging from 0 to 100, ±SD. A higher score represents a higher level of fatigue/interference with daily
life/social sequelae.
zClinical signiﬁcance according to Osoba et al28: diﬀerences of Z10 points on the EORTC scales are regarded as clinically signiﬁcant.
yHADS-D mean score, ranging from 0 to 21, ±SD. A higher score represents a higher level of depression symptoms. The clinical signiﬁcance approach of
Osoba et al28 does not apply for the HADS-D score.
8Standardized EORTC QLQ-C30 mean scores, ranging from 0 to 100, ±SD. On the global score and functioning scales a higher score represents a better
HRQOL and functioning. For the symptom scales a higher score represents a higher level of symptoms.
EORTC QLD-C30 indicates European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLD-FA13, European
Organization for Research and Treatment of Cancer fatigue module; HADS-D, Hospital Anxiety and Depression Scale; IFN-a, interferon-a.
global HRQOL
physical fatigue depression
FIGURE 1. Course of physical fatigue depression and global health-related quality of life (HRQOL) of the 2 comparison groups.
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of exhaustion, tiredness and lack of energy in the ﬁrst
months of treatment, than feelings of frustration, help-
lessness, discouragement, and concentration deﬁcits. This
predominantly physical fatigue burden is experienced by
many patients as interfering with their daily life. Therefore,
IFN-a side eﬀect management should focus on this physical
fatigue syndrome, implementing psychosocial interventions
speciﬁcally aimed at reducing fatigue, which teach patients
coping techniques and eﬀective activity management.31 A
recent review on IFN-a-related fatigue oﬀers helpful patient
guidelines for the management of fatigue.13 The authors
also point out the strong association of fatigue and
depression and the diﬃculty in their distinction. Our ﬁnd-
ings suggest that patients suﬀer considerably more from
fatigue than from depression. The potential overlap of
physical fatigue and depression in symptoms like lack of
energy, exhaustion, and tiredness might be 1 reason for
overestimation of depression in other IFN-a trials.32 In
addition, only few IFN-a trials applied speciﬁc depression
questionnaires.
The generally low mean depression scores of both the
treatment and nontreatment group are a striking but
unsurprising ﬁnding of our study. Heinze et al15 assessing
depressive mood changes under low-dose IFN-a with the
Beck Depression Inventory (BDI) also report low mean
BDI scores, with only 5% of the IFN-a patients developing
clinically signiﬁcant depressive syndromes under IFN-a.
Our data showed mean depression scores in both groups
which stayed below normative mean values of the general
German population for the whole assessment period,33
conﬁrming earlier ﬁndings of melanoma patients being in
general less burdened by psychological distress than other
cancer patients.9,15,17,32 However, patients in the treatment
group showed statistically signiﬁcant higher HADS-D
scores than in the nontreatment group, but the number of
patients with highly elevated depression levels did not diﬀer
between both groups. The study examined the initial eﬀects
of IFN-a within the ﬁrst 6 months of treatment, in
accordance to others who have pointed out that most side
eﬀects occur in this ﬁrst treatment phase.9–10,15 However,
depression can also develop as a function of dose and
duration15,18 and should therefore be closely monitored by
clinicians throughout the 18 months of treatment to prevent
the development of mood disorders.
Summarizing we found IFN-a patients in the Skin
Cancer Centers in Freiburg and Cologne to experience an
increase in predominantly physical fatigue, concomitant with
an interference with daily life and an also clinically signiﬁcant
increase in dyspnea and appetite loss. These ﬁndings on
physical side eﬀects conﬁrm previous studies and especially
appetite loss has shown to be a frequent complain that needs
to be addressed with adequate measures in IFN-a side eﬀect
management.9–12,29 In contrast, depression symptoms did not
increase signiﬁcantly in the ﬁrst months of IFN-a treatment.
We believe that our study’s diﬀerentiated assessment of fati-
gue, depression, and HRQOL at the onset of low-dose IFN-a
in comparison with a nontreatment group is a useful and
innovative means of investigating relevant biopsychosocial
eﬀects of low-dose IFN-a in routine clinical practice. This
observational study design in the routine practice setting
entails the chance to close the knowledge gap on HRQOL of
patients in routine care units.29 The nonrandomized study
design should, however, also be mentioned as a caveat of the
comparison, leading to a limitation of internal validity of our
ﬁndings and restricting the comparison with ﬁndings in cancer
trial settings. As treatment decisions regarding IFN-a were
not made under study conditions but in clinical practice,
possible bias in selecting patients for treatment might have led
to underestimation of depression. Dermatooncologists might
screen out patients for IFN-a treatment with preexisting
burden. Further research on these potential processes in
clinical practice along with the examination of long-term
eﬀects of low-dose IFN-a are important propositions for
further research.
TABLE 3. General Linear Model Results for Fatigue, Depression, and Global HRQOL
Scales Eﬀect F (df) P g2
EORTC QLQ-FA13
Physical fatigue
Time eﬀect 6.98 (2, 188) 0.001** 0.069
Group eﬀect 14.59 (1, 94) 0.000** 0.134
Timegroup 9.12 (2, 188) 0.000** 0.088
EORTC QLQ-FA13
Emotional fatigue
Time eﬀect 0.16 (2, 188) 0.849 0.002
Group eﬀect 2.6 (1, 94) 0.108 0.027
Timegroup 0.77 (2, 188) 0.464 0.008
EORTC QLQ-FA13
Cognitive fatigue
Time eﬀect 0.38 (2, 188) 0.685 0.004
Group eﬀect 8.19 (1, 94) 0.005** 0.080
Timegroup 2.50 (2, 188) 0.085 0.026
HADS-D
Depression Scale
Time eﬀect 0.37 (2, 188) 0.693 0.004
Group eﬀect 6.75 (1, 94) 0.011* 0.067
Timegroup 2.76 (2, 188) 0.066 0.028
EORTC QLQ-C30
Global HRQOL
Time eﬀect 5.80 (2, 188) 0.004** 0.058
Group eﬀect 5.34 (1, 94) 0.023* 0.054
Timegroup 3.87 (2, 188) 0.023* 0.040
*Pr0.05.
**Pr0.01.
EORTC QLD-C30 indicates European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLD-FA13, European
Organization for Research and Treatment of Cancer fatigue module; HADS-D, Hospital Anxiety and Depression Scale; HRQOL, health-related quality of life.
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